Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?

Pashaei, Yaser

doi:10.1016/j.jocn.2021.03.010

Cited by 38 publications

(33 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, most of our patients were treated with vitamin D which could have a protective role against COVID-19 [20,21] even if there is no consensus on the reduction of the risk of severe evolution of COVID-19 in patients without deficit in a metaanalysis [22]. Moreover, a third of adults with PWS in our cohort were on antidepressants, that may have a beneficial effect on the course of COVID-19 [23,24]. Finally, 10 adults with diabetes took Metformin (83% of diabetics) which reduced the mortality of hospitalized patients with COVID-19 and type 2 diabetes in several studies [25][26][27], but it is difficult to know if Metformin is a witness of less severe diabetes or if it has a specific effect on COVID-19 in these studies.…”

Section: Discussionmentioning

confidence: 99%

Paradoxical low severity of COVID-19 in Prader-Willi syndrome: data from a French survey on 647 patients

Coupaye

Laurier

Benvegnu

et al. 2021

Orphanet J Rare Dis

View full text Add to dashboard Cite

Background Patients with Prader-Willi syndrome (PWS) often have comorbidities, especially obesity, that may constitute a risk factor for severe forms of COVID-19. We aimed to assess prevalence and medical course of SARS-CoV-2 infection in children and adults with PWS. From November 2020 to January 2021, we performed a detailed medical survey on 342 adults and 305 children with PWS followed in the French reference center. Results We obtained responses from 288 adults (84%) and 239 children (78%). From March 2020 to January 2021, 38 adults (13.2%) and 13 children (5.4%) with PWS had SARS-CoV-2 infection. Mean age of adults was 34.1 ± 11.9 years and mean body mass index was 40.6 ± 12.7 kg/m2; 82% had obesity and 37% had diabetes. Only 3 children (23%) had obesity and none had diabetes. Similar to the general population, the most frequent symptoms of COVID-19 were asthenia, fever, cough, headache and shortness of breath. All patients had a favorable outcome. Conclusion PWS itself is not a risk factor for severe COVID-19 in children and adults. On the contrary, evolution of SARS-CoV-2 infection in adults with PWS seems more favorable than expected, given their comorbidities.

show abstract

Section: Discussionmentioning

confidence: 99%

Paradoxical low severity of COVID-19 in Prader-Willi syndrome: data from a French survey on 647 patients

Coupaye

Laurier

Benvegnu

et al. 2021

Orphanet J Rare Dis

View full text Add to dashboard Cite

show abstract

“…There are studies indicating the progression of cognitive dysfunction after the inclusion of antidepressants [211,212]. Previous knowledge indicates that, among the selective serotonin reuptake inhibitors (SSRIs) group antidepressants, fluoxetine is a promising drug against COVID-19 through its effect on reducing the secretion of inflammatory cytokines/chemokines (IL-6,CCL-2,TNF-α) and immunomodulatory properties [32,209,210]. In addition, fluoxetine exhibits antiviral activity and is effective against SARS-CoV-2 in cell cultures [32].…”

Section: Antidepressant Treatment and Covid-19mentioning

confidence: 99%

“…Previous knowledge indicates that, among the selective serotonin reuptake inhibitors (SSRIs) group antidepressants, fluoxetine is a promising drug against COVID-19 through its effect on reducing the secretion of inflammatory cytokines/chemokines (IL-6,CCL-2,TNF-α) and immunomodulatory properties [32,209,210]. In addition, fluoxetine exhibits antiviral activity and is effective against SARS-CoV-2 in cell cultures [32]. This indicates the possible alleviation of neuropsychiatric complications after COVID-19 by fluoxetine use [32].…”

Section: Antidepressant Treatment and Covid-19mentioning

confidence: 99%

“…In this review, we focus on the problem of depressive and neurocognitive disorders in the face of COVID-19, the pathogenesis of SARS-CoV-2 infection, its long-term consequences for the body and potential therapeutic interventions, including antidepressant treatment. The studies conducted so far indicate the immunomodulatory and antiviral properties of antidepressant treatment, which may appear effective in counteracting neuropsychiatric complications after COVID-19 [32,33].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19

Dąbrowska

Galińska-Skok

Waszkiewicz

2021

Life

View full text Add to dashboard Cite

The dysfunctional effects of the coronavirus disease 2019 (COVID-19) infection on the nervous system are established. The manifestation of neuropsychiatric symptoms during and after infection is influenced by the neuroinvasive and neurotrophic properties of SARS-CoV-2 as well as strong inflammation characterised by a specific “cytokine storm”. Research suggests that a strong immune response to a SARS-CoV-2 infection and psychological stressors related to the pandemic may cause chronic inflammatory processes in the body with elevated levels of inflammatory markers contributing to the intensification of neurodegenerative processes. It is suggested that neuroinflammation and associated central nervous system changes may significantly contribute to the etiopathogenesis of depressive disorders. In addition, symptoms after a COVID-19 infection may persist for up to several weeks after an acute infection as a post-COVID-19 syndrome. Moreover, previous knowledge indicates that among SSRI (selective serotonin reuptake inhibitor) group antidepressants, fluoxetine is a promising drug against COVID-19. In conclusion, further research, observation and broadening of the knowledge of the pathomechanism of a SARS-CoV-2 infection and the impact on potential complications are necessary. It is essential to continue research in order to assess the long-term neuropsychiatric effects in COVID-19 patients and to find new therapeutic strategies.

show abstract

“…Thus, peripheral serotonin plays an important role in modulating both innate and adaptive immune responses and inflammation. Most recently, serum serotonin levels have been considered a good predictor for the outcome of SARS-CoV-2 infection [ 7 ] and its potential role as a therapeutic target for COVID-19 treatment is being explored [ 8 ].…”

mentioning

confidence: 99%

Serotonin is a multifaceted player in the immune response

Lin

2021

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

show abstract

Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?

Abstract: Graphical abstract

Cited by 38 publications

References 137 publications

Paradoxical low severity of COVID-19 in Prader-Willi syndrome: data from a French survey on 647 patients

Paradoxical low severity of COVID-19 in Prader-Willi syndrome: data from a French survey on 647 patients

Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19

Serotonin is a multifaceted player in the immune response

Contact Info

Product

Resources

About